A phase II trial of cetuximab [Erbitux], radiotherapy and twice weekly gemcitabine [Gemzar] in patients wtih adenocarcinoma of the pancreas.
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2014
At a glance
- Drugs Cetuximab (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 24 Jun 2011 Planned end date changed from 1 Feb 2010 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 13 Nov 2005 New trial record.